180 related articles for article (PubMed ID: 34898561)
1. Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden.
Kang NW; Tan KT; Li CF; Kuo YH
Curr Oncol; 2021 Nov; 28(6):4587-4596. PubMed ID: 34898561
[TBL] [Abstract][Full Text] [Related]
2. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.
Mohamed A; Azmi AS; Asa SL; Tirumani SH; Mahipal A; Cjakrabarti S; Bajor D; Selfridge JE; Kaseb AO
Curr Oncol; 2022 Nov; 29(11):9018-9030. PubMed ID: 36421360
[TBL] [Abstract][Full Text] [Related]
3. Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix.
Paterniti TA; Dorr K; Ullah A; White J; Williams H; Ghamande S
Obstet Gynecol; 2021 Nov; 138(5):813-816. PubMed ID: 34619736
[TBL] [Abstract][Full Text] [Related]
4. High grade neuroendocrine carcinoma of the breast, first line and maintenance immunotherapy.
Symeonidis D; Papageorgiou G; Liatsos A; Trihia H; Lianos E; Kosmas C
Anticancer Drugs; 2022 Jan; 33(1):91-93. PubMed ID: 34232940
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
[TBL] [Abstract][Full Text] [Related]
6. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
Sharabi A; Kim SS; Kato S; Sanders PD; Patel SP; Sanghvi P; Weihe E; Kurzrock R
Oncologist; 2017 Jun; 22(6):631-637. PubMed ID: 28550027
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.
Wang VE; Urisman A; Albacker L; Ali S; Miller V; Aggarwal R; Jablons D
J Immunother Cancer; 2017 Sep; 5(1):75. PubMed ID: 28923100
[TBL] [Abstract][Full Text] [Related]
9. Abscopal effect of radiation therapy and nivolumab in a patient with combined small-cell lung cancer: a case report.
Wang W; Li L; Wu S; Shen J; Huang C; Chen Y; Li S
Immunotherapy; 2022 Aug; 14(12):909-914. PubMed ID: 35787148
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab exerts therapeutic effects against metastatic lesions from early gastric adenocarcinoma with a small proportion of neuroendocrine carcinoma after gastrectomy: a case report.
Sawayama H; Komohara Y; Hirao H; Sakata K; Takata N; Yoshinaka I; Harada K; Baba H
Clin J Gastroenterol; 2020 Oct; 13(5):759-765. PubMed ID: 32592148
[TBL] [Abstract][Full Text] [Related]
11. Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC).
Mohamed A; Vijayvergia N; Kurian M; Liu L; Fu P; Das S
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681675
[No Abstract] [Full Text] [Related]
12. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas.
Gile JJ; McGarrah PW; Leventakos K; Sonbol MB; Starr JS; Eiring RA; Hobday TJ; Halfdanarson TR
J Neuroendocrinol; 2023 May; 35(5):e13283. PubMed ID: 37229903
[TBL] [Abstract][Full Text] [Related]
14. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas.
Chen MH; Chou WC; Hsiao CF; Jiang SS; Tsai HJ; Liu YC; Hsu C; Shan YS; Hung YP; Hsich CH; Chiu CH; Liu TC; Cho SF; Liu TW; Chao Y
Oncologist; 2020 May; 25(5):e782-e788. PubMed ID: 31852810
[TBL] [Abstract][Full Text] [Related]
15. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
Ready N; Farago AF; de Braud F; Atmaca A; Hellmann MD; Schneider JG; Spigel DR; Moreno V; Chau I; Hann CL; Eder JP; Steele NL; Pieters A; Fairchild J; Antonia SJ
J Thorac Oncol; 2019 Feb; 14(2):237-244. PubMed ID: 30316010
[TBL] [Abstract][Full Text] [Related]
16. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
De Divitiis C; von Arx C; Grimaldi AM; Cicala D; Tatangelo F; Arcella A; Romano GM; Simeone E; Iaffaioli RV; Ascierto PA; Tafuto S;
J Transl Med; 2016 May; 14(1):113. PubMed ID: 27142424
[TBL] [Abstract][Full Text] [Related]
17. Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab.
Oda R; Okuda K; Yamashita Y; Sakane T; Tatematsu T; Yokota K; Endo K; Nakanishi R
Thorac Cancer; 2020 Jul; 11(7):2036-2039. PubMed ID: 32379390
[TBL] [Abstract][Full Text] [Related]
18. Durable response to combination radiotherapy and immunotherapy in EP-resistant lung large-cell neuroendocrine carcinoma with
Qin Y; Yu M; Zhou L; Jiang L; Huang M
Immunotherapy; 2020 Mar; 12(4):223-227. PubMed ID: 32156177
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab for the treatment of small cell lung cancer.
Simeone E; Grimaldi AM; Festino L; Trojaniello C; Vitale MG; Vanella V; Curvietto M; Ascierto PA
Expert Rev Respir Med; 2020 Jan; 14(1):5-13. PubMed ID: 31622114
[No Abstract] [Full Text] [Related]
20. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.
Dasari A; Mehta K; Byers LA; Sorbye H; Yao JC
Cancer; 2018 Feb; 124(4):807-815. PubMed ID: 29211313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
